DIVISLAB:NSE:NSE-Divi's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 6048.3

Change

0.00 (0.00)%

Market Cap

USD 1,561.24B

Volume

0.43M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MANKIND:NSE Mankind Pharma Ltd

-53.00 (-1.80%)

USD 1,185.39B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-2.30 (-0.17%)

USD 1,157.53B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-39.90 (-1.17%)

USD 1,152.44B
LUPIN:NSE Lupin Limited

-8.55 (-0.36%)

USD 1,016.49B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-14.35 (-1.47%)

USD 978.76B
AUROPHARMA:NSE Aurobindo Pharma Limited

-6.65 (-0.50%)

USD 737.59B
ALKEM:NSE Alkem Laboratories Limited

+24.35 (+0.44%)

USD 665.89B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-12.35 (-0.75%)

USD 447.54B
IPCALAB:NSE IPCA Laboratories Limited

-16.00 (-0.92%)

USD 421.90B
AJANTPHARM:NSE Ajanta Pharma Limited

+73.50 (+2.56%)

USD 380.23B

ETFs Containing DIVISLAB:NSE

KMED 0.00 % 0.79 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.41% 37% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.41% 37% F 30% F
Trailing 12 Months  
Capital Gain 51.15% 71% C- 78% C+
Dividend Return 0.75% 60% D- 56% F
Total Return 51.89% 71% C- 78% C+
Trailing 5 Years  
Capital Gain 228.02% 50% F 53% F
Dividend Return 6.83% 61% D- 46% F
Total Return 234.85% 50% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 16.99% 30% F 26% F
Dividend Return 17.58% 32% F 26% F
Total Return 0.59% 62% D 48% F
Risk Return Profile  
Volatility (Standard Deviation) 40.22% 67% D+ 63% D
Risk Adjusted Return 43.71% 34% F 24% F
Market Capitalization 1,561.24B 100% F 97% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.